One patient had a single brain metastasis and received comprehensive treatment including surgery, radiotherapy, chemotherapy, PD-1 inhibitor (tislelizumab), and PARP inhibitor (niraparib). The immune microenvironment characteristics of brain metastases (e.g., high PD-L1 expression, T-cell infiltration) may predict the efficacy of immunotherapy, but the prognosis for patients with multiple brain metastases remains poor. Further research is needed to explore the correlation between peripheral blood immune markers and treatment response in brain metastases.

3 days ago

Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)

PD-L1 expression • PD-L1 overexpression • HRD

Tevimbra (tislelizumab-jsgr) • Zejula (niraparib)

Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report. (PubMed, Transl Lung Cancer Res)

The patient received four cycles of tislelizumab combined with albumin-bound paclitaxel and carboplatin, followed by four cycles of tislelizumab monotherapy maintenance. The distinct marker expression profile in subcutaneous metastatic lesions (high CD56, PD-1, and pan-CK expression with low CD8, CD68, and CD20 expression) reflects the unique TME of SMARCA4-UT, which may be related to its metastatic potential and immunotherapeutic response. Chemotherapy combined with immunotherapy shows promising efficacy in the treatment of SMARCA4-UT, and the mIF-based marker profile may provide a potential basis for optimizing individualized treatment strategies.

3 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule)

carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel

The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study (clinicaltrials.gov)

P=N/A, N=715, Completed, Tongji Hospital

8 days ago

New trial

Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Stivarga (regorafenib) • Zepsun (donafenib)

CJDQ443B12105B: Rollover study for participants who are currently being treated with and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments. (2025-523537-26-00)

P1/2, N=16, Not yet recruiting, Novartis Pharma AG

8 days ago

New P1/2 trial

Erbitux (cetuximab) • Tevimbra (tislelizumab-jsgr) • batoprotafib (TNO155) • opnurasib (JDQ443)

The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer (clinicaltrials.gov)

P=N/A, N=30, Active, not recruiting, Guangzhou Medical University

8 days ago

New trial

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation

Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study (clinicaltrials.gov)

P2, N=130, Completed, The First Affiliated Hospital with Nanjing Medical University | Recruiting --> Completed | Trial completion date: Jul 2027 --> Jun 2026 | Trial primary completion date: Dec 2025 --> May 2026

9 days ago

Trial completion • Trial completion date • Trial primary completion date

Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin

ZeTA: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (clinicaltrials.gov)

P2, N=76, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Apr 2026 --> Apr 2029

9 days ago

Trial completion date • Trial primary completion date

Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib)

10d

KontRASt-R: Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments (clinicaltrials.gov)

P1/2, N=40, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

10 days ago

Enrollment open

Erbitux (cetuximab) • Mekinist (trametinib) • Tevimbra (tislelizumab-jsgr) • batoprotafib (TNO155) • opnurasib (JDQ443)

10d

HFB-200603-01: A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=83, Active, not recruiting, HiFiBiO Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

10 days ago

Trial completion date • Trial primary completion date

BRAF (B-raf proto-oncogene)

BRAF V600

Tevimbra (tislelizumab-jsgr) • HFB200603

10d

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） (clinicaltrials.gov)

P3, N=500, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.

10 days ago

New P3 trial

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

ALK fusion

cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010